Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Effective Interest Rate on Debt % is the usage rate that a borrower actually pays on a debt. It is calculated as the positive value of Interest Expense divided by its average total debt. Total debt equals to Long-Term Debt & Capital Lease Obligation plus Short-Term Debt & Capital Lease Obligation. Verici Dx's annualized positive value of Interest Expense for the quarter that ended in Dec. 2025 was $0.02 Mil. Verici Dx's average total debt for the quarter that ended in Dec. 2025 was $0.24 Mil. Therefore, Verici Dx's annualized Effective Interest Rate on Debt % for the quarter that ended in Dec. 2025 was 6.68%.
Verici Dx (OTCPK:VRCDF) Effective Interest Rate on Debt % Explanation
Effective Interest Rate on Debt % measures the usage rate that a borrower actually pays on a debt.
Verici Dx Effective Interest Rate on Debt % Related Terms
Verici Dx Effective Interest Rate on Debt % Historical Data
* Premium members only.
The historical data trend for Verici Dx's Effective Interest Rate on Debt % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
VRCDF vs TMO, DHR, IDXX: Effective Interest Rate on Debt % Comparison
For the Diagnostics & Research subindustry, Verici Dx's Effective Interest Rate on Debt %, along with its competitors' market caps and Effective Interest Rate on Debt % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Verici Dx Effective Interest Rate on Debt % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Verici Dx's Effective Interest Rate on Debt % distribution charts can be found below:
* The bar in red indicates where Verici Dx's Effective Interest Rate on Debt % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Effective Interest Rate on Debt %, the Interest Expense of the last fiscal year and the average total debt over the fiscal year are used. In calculating the quarterly data,
the Interest Expense data used here is two times the semi-annual (Dec. 2025) interest expense data.
Effective Interest Rate on Debt % is displayed in the 30-year financial page.
What does a Effective Interest Rate on Debt % of 6.68% mean?
Verici Dx (VRCDF) has a Effective Interest Rate on Debt % of 6.68% as of Dec. 2025. Effective interest rate on debt is the rate a company actually pays on its debt. View historical data on Verici Dx and its competitors.
Is Verici Dx's Effective Interest Rate on Debt % too high?
Verici Dx's current Effective Interest Rate on Debt % is 6.68%.
How does Verici Dx's Effective Interest Rate on Debt % compare to TMO and DHR?
Verici Dx's Effective Interest Rate on Debt % of 6.68% can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Effective Interest Rate on Debt % for a Medical Diagnostics & Research company?
A good Effective Interest Rate on Debt % depends on the Medical Diagnostics & Research industry context. However, Effective Interest Rate on Debt % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Effective Interest Rate on Debt % mean?
A high Effective Interest Rate on Debt % can signal that a stock is expensive relative to its fundamentals. Effective interest rate on debt is the rate a company actually pays on its debt. View historical data on Verici Dx and its competitors. Verici Dx's current Effective Interest Rate on Debt % is 6.68%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Verici Dx stock overvalued right now?
Verici Dx (VRCDF) has a current Effective Interest Rate on Debt % of 6.68%. The current Effective Interest Rate on Debt % is 6.68%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Effective Interest Rate on Debt % calculated?
Effective Interest Rate on Debt % is calculated from a company's financial statements. For Verici Dx (VRCDF), the current Effective Interest Rate on Debt % is 6.68% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Verici Dx PLC is an immuno-diagnostics development company. The company is focused on the development of prognostic and diagnostic tests for kidney transplant patients. There are two products for clinical validation and commercialization: Clarava, which is a pre-transplant prognosis for the risk of early acute rejection; Tuteva, a post-transplant diagnostic focused upon acute cellular rejection, including sub-clinical rejection not being diagnosed through the current standard of care of rising serum creatine levels; and Protega will utilize RNA gene signatures to more accurately risk stratify outcome from fibrosis in a transplant patient. The business of the Group comprises a single activity, which of the development of prognostic and diagnostic tests for kidney transplant patients.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
VRCDF has been successfully added to your 
